In this articleMC-FRA view of a Sephora beauty product store on May 30, 2025 in Sherman Oaks, California. Justin Sullivan | Getty ImagesItalian regulators are looking to clamp down on the tween skincare obsession and are investigating the LVMH-owned cosmetic brands Sephora and Benefit over an "insidious" marketing campaign to children. The Italian Competition Authority (AGCM) said Friday that it has launched investigations into the two cosmetic brands centred on "unfair commercial practices," which saw chil ...

Core Insights - Resmed Inc. reported adjusted earnings per share (EPS) of $2.81 for Q2 fiscal 2026, reflecting a 15.6% year-over-year increase and surpassing the Zacks Consensus Estimate by 4.59% [2] - The company's total revenue for the quarter reached $1.42 billion, marking an 11% year-over-year growth, also exceeding the Zacks Consensus Estimate by 2.30% [3] Revenue Performance - Revenues from the Sleep and Breathing Health segment increased by 11.6% year over year to $1.26 billion, with Devices revenues at $726.2 million, up 8.5% [5] - The Masks and other category generated $529.7 million, up 16.1% year over year, driven by strong growth in both the U.S. and international markets [6] - The Residential Care Software segment saw a revenue increase of 6.6% year over year, totaling $166.9 million [7] Margin and Profitability - The adjusted gross profit rose 17.3% to $890.5 million, with an adjusted gross margin of 62.6%, reflecting a 340 basis point expansion [8] - The adjusted operating profit for the quarter was $521.2 million, up 19.6% year over year, with an adjusted operating margin of 36.6%, expanding by 263 basis points [10] Financial Position - At the end of Q2 fiscal 2026, Resmed had cash and cash equivalents of $1.42 billion, an increase from $1.38 billion at the end of Q1 [11] - The cumulative net cash provided by operating activities was $797.1 million, compared to $634.2 million in the same period last year [11] - The company paid out $88 million in dividends and repurchased 704,000 shares for $175 million during the quarter [12] Strategic Developments - Resmed received FDA clearance for its Personalized Therapy Comfort Settings, marketed as Smart Comfort, aimed at enhancing CPAP comfort settings and improving patient adherence [15] - The performance of the Residential Care Software segment is bolstered by contributions from the Medifox DAN software vertical, targeting sustainable growth [14]

Core Insights - Resmed reported strong financial results for the quarter ended December 31, 2025, with an 11% year-over-year revenue growth, driven by high demand for sleep and respiratory care devices and the expansion of its digital health ecosystem [3][5][21]. Financial Performance - Revenue for the quarter reached $1.422 billion, an increase of 11% compared to $1.282 billion in the same quarter of the previous year, with a 9% increase on a constant currency basis [4][5][21]. - Gross margin improved by 320 basis points to 61.8%, while non-GAAP gross margin increased by 310 basis points to 62.3%, attributed to manufacturing efficiencies and cost improvements [5][8][21]. - Income from operations rose by 18% to $491.7 million, with non-GAAP income from operations increasing by 19% to $517.2 million [4][5][21]. - Net income for the quarter was $392.6 million, a 14% increase from $344.6 million, with non-GAAP net income rising by 15% to $411.5 million [5][20]. - Diluted earnings per share increased by 15% to $2.68, while non-GAAP diluted earnings per share rose by 16% to $2.81 [5][20]. Operational Highlights - The company continues to invest in innovation to enhance its digital health capabilities and expand access to care [4][8]. - Operating cash flow for the quarter was $340 million, reflecting strong operational performance [5][17]. - Resmed declared a quarterly cash dividend of $0.60 per share, with a record date of February 12, 2026 [8][9]. Market Performance - Revenue growth was driven by a 11% increase in the U.S., Canada, and Latin America, while Europe, Asia, and other markets saw a 6% growth on a constant currency basis [8][21]. - The company reported a 5% increase in Residential Care Software revenue on a constant currency basis [8][21]. Strategic Initiatives - Resmed received FDA clearance for an AI-enabled digital medical device aimed at personalizing CPAP comfort settings, enhancing patient adherence [8]. - The company presented its long-term growth opportunities and leadership in digital sleep and respiratory health at the J.P. Morgan Healthcare Conference [8].

Core Insights - Resmed Inc. reported a strong start to fiscal year 2026, with a 9% year-over-year revenue growth and significant improvements in gross margins and earnings per share [2][3][5] Financial Performance - Revenue for the quarter ended September 30, 2025, was $1,335.6 million, up from $1,224.5 million in the same quarter of 2024, reflecting a 9% increase [4][5][21] - Non-GAAP gross margin improved by 280 basis points to 62.0%, while GAAP gross margin increased by 290 basis points to 61.5% [5][21] - Non-GAAP diluted earnings per share rose by 16% to $2.55, compared to $2.20 in the prior year [5][19] Operational Highlights - Income from operations increased by 15% to $446.5 million, with non-GAAP income from operations rising by 19% to $482.1 million [5][19] - Operating cash flow for the quarter was $457 million, indicating strong cash generation capabilities [5][17] - The company declared a quarterly cash dividend of $0.60 per share, payable on December 18, 2025 [8] Market and Product Insights - Revenue growth was driven by increased demand for sleep devices, masks, and accessories, with U.S., Canada, and Latin America revenue growing by 10% [9][21] - The company launched the Sleep Institute to promote sleep health as a public health priority and published a study projecting a significant increase in obstructive sleep apnea cases by 2050 [9][11] Strategic Initiatives - Resmed is committed to ongoing operational excellence and strategic investments in innovation to ensure sustainable growth [4][9] - The company recorded $16 million in restructuring-related charges as part of workforce planning aligned with its 2030 strategic priorities [9]

Core Insights - WORK Medical Technology Group Ltd. is exploring real-world asset (RWA) tokenization and blockchain technology through a partnership with the Hong Kong Web3.0 Standardization Association, aiming to leverage its existing product infrastructure and AI business [3][4][11] - The company has outlined three main areas for collaboration: tokenization of high-quality assets, equity investments, and development of RWA technology [6][7][9] Company Strategy - The partnership aligns with WORK Medical's "Healthcare + Payment + Technology = RWA + Web3 + AI" strategy, which aims to integrate various sectors for growth [4] - The company plans to collaborate with qualified firms in the financial sector to ensure compliance in its asset tokenization efforts [4] Market Potential - Tokenized RWAs are projected to exceed $50 billion by the end of the year, with U.S. treasuries expected to dominate this market, contributing over $28 billion [5] Collaboration Areas - The first area of collaboration focuses on tokenizing high-quality assets owned or invested in by WORK Medical, potentially including receivables, investment products, and intellectual property [6] - The second area involves equity investments, which may include co-investments or participation in funds to accelerate RWA tokenization [7] - The third area is the development of RWA technology, utilizing the Hong Kong Web3.0 Association's RWA registration platform for regulatory compliance and asset security [9] Recent Developments - WORK Medical has also formed a partnership with Ruijin Hospital's Wuxi Branch to advance AI-driven healthcare solutions, integrating multimodal medical data [12][13] - The company's revenue from its mask business fell 69% to $1.6 million, while revenue from other medical devices increased by 18% to $9.4 million [16] - The company generated $400,000 from commodities trading and $15.7 million from financing activities in its latest fiscal year [17]